| Bioactivity | Regavirumab (MCA C23) is a human monoclonal antibody against cytomegalovirus (CMV), human serum albumin (HSA) and amino acetic acid[1]. |
| In Vivo | 注射 Regavirumab 后获得的大鼠血清显示出强大的抑制斑块形成的活性[1]。Regavirumab (2 mg/kg/周，5次)，第4次注射后24 h, Regavirumab 血药浓度达到稳定状态 (74.4±11.8 μg/mL)。末次注射后的消除半衰期与单次注射后相似[1]。 |
| Name | Regavirumab |
| CAS | 153101-26-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Arizono H, et al. Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys. Arzneimittelforschung. 1994 Jul;44(7):909-13. |